Zydus Cadila has received final approval from the USFDA to market Telmisartan tablets, 20mg, 40mg and 80mg.  

The estimated sales in 2014 for Telmisartan tablets which fall in the anti-hypertensive segment is USD 233.3 million, as per IMS.

The group now has 96 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.
 

Shares of the company declined Rs 31.50, or 2.56%, to settle at Rs 1,200.40 at the BSE (Thursday).